Related Experiment Video

Updated: Mar 22, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K

Anti-CCR5 Therapy Circumvents Immune Cell Exploitation by Tumors

    Cancer Discovery
    |April 30, 2016
    PubMed

    Insights

    T cells at the invasive edges of colorectal cancer metastases release CCL5, a protein that fuels tumor expansion. This finding highlights a key mechanism driving metastatic colorectal cancer progression.

    Area of Science:

    • Immunology
    • Oncology
    • Cancer Biology

    Background:

    • Colorectal cancer (CRC) metastasis is a major cause of mortality.
    • Tumor microenvironment (TME) plays a critical role in cancer progression.
    • T cells are immune cells found within the TME.

    Discussion:

    • CCL5, a chemokine, is secreted by T cells at the invasive margins of CRC metastases.
    • CCL5 signaling promotes tumor cell proliferation and invasion.
    • This suggests a pro-tumorigenic role for T cell-derived CCL5 in CRC metastasis.

    Key Insights:

    • T cells contribute to colorectal cancer growth at metastatic sites.
    • CCL5 is a key mediator of this T cell-driven tumor promotion.
    • Targeting CCL5 may offer a therapeutic strategy for metastatic CRC.

    Outlook:

    • Further investigation into the precise mechanisms of CCL5 action in CRC metastasis.
    • Exploring the potential of CCL5 inhibitors as a treatment for metastatic colorectal cancer.
    • Evaluating the role of different T cell subsets in CCL5 production and its impact on CRC progression.

    More Related Videos

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    9.7K
    Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

    Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

    Published on: February 14, 2025

    2.0K

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    1.7K
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K
    Cytotoxic T Cells-mediated Immune Response01:27

    Cytotoxic T Cells-mediated Immune Response

    Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
    Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
    7.8K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K